Ilya Pharma presents at Uppsala University Pharmaceutical Science Day 1st February in Uppsala
News
Ilya Pharma is attending the 42nd Annual J.P. Morgan Healthcare Conference in SF 8-11 Jan
Seminar at SciLifeLabs by Professor Neil Forbes - pioneer of genetically modified bacteria for treatment of solid tumors
Today there are >20 drug candidates that are genetically modified bacteria have been or are evaluated in clinical trials in a wide range of medical indications.
Nailing of a Doctoral Thesis
"Promoting healing of skin and mucosa by immunomodulation using CXCL12 producing lactic acid bacteria: From bench to bedside" by Industrial PhD student Emelie Öhnstedt.
Ilya Pharma is participating in the Jefferies Healthcare Conference in London, Nov 14-16
Interested in learning more about Ilyas's ILP-technology, local-acting immunotherapies or any of the trials SITU-SAFE, SITU-SURGERY, SITU-HEAL or SITU-GUT or our recent work in AMR and meet our CEO Evelina Vågesjö, please reach out.
Nailing of a Thesis - "Live Biotherapeutics - Importance of formulation and lyophilization parameters and an example of a clinical application"
The thesis will be defended in a hearing open to the public at the Swedish University of Agricultural Sciences on Tuesday 5th September (09:00-12:00) in Undervisningshuset Sal L, SLU, Uppsala.
Dr Andreas Fasth will present the planned SITU-SURGERY trial at the US Military partnering conference MHSRS in Kissimmee, FL on August 16
For the third consecutive year Ilya Pharma is invited to share updates regarding its ILP100-Topical program to the US Military largest medical conference, Military Health Systems Research Symposium (MHSRS).